The Genomic Editing and Screening (GES) Core was established in 2012 with institutional funds. Initially, it provided cutting-edge RNA interference (RNAi) gene target knockdown technologies toward the discovery of novel cancer targets and elucidation of complex aberrant intracellular pathways. A central feature is the use of third generation Pol II-driven, enhanced Mir30-based shRNA for high functional protein knockdown efficiency at single-copy integration, using a diverse panel of packaged retro-and lentiviral plasmid backbones for effective delivery. Establishment of this platform subsequently allowed for the rollout in 2014 of CRISPR-Cas9 sgRNA single-gene and full-genome knockout technologies via pooled libraries. Realization that many cell types are easily transfectable and that discrete intracellular events such as activation, translocation, and cell- to-cell communication can be quantified using high-speed automated fluorescence microscopy, the Core initiated high content imaging and analysis (HCA) for arrayed siRNA experimentation. A natural extension of this 96/384 well plate format was then evolved into a workstation-based small molecule compound screening program, allowing investigators to effectively phenocopy newly-identified targets using chemical biology approaches. The most promising of these compounds are then matriculated into the Early Therapeutics Center (ETC) and Tri-Institutional Therapeutic Drug Initiative (TRI-I TDI). Overall, this multi-modal Core enables mechanism-based science through target identification and drug screening, offering custom reagents and services to a growing number of the Center?s members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084837
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Jakub, James W; Peled, Anne Warren; Gray, Richard J et al. (2018) Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg 153:123-129
Ulaner, Gary A; Lyashchenko, Serge K; Riedl, Christopher et al. (2018) First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. J Nucl Med 59:900-906
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
McFarland, Daniel C; Shaffer, Kelly M; Tiersten, Amy et al. (2018) Physical Symptom Burden and Its Association With Distress, Anxiety, and Depression in Breast Cancer. Psychosomatics 59:464-471
Aherne, Emily A; Plodkowski, Andrew J; Montecalvo, Joseph et al. (2018) What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology? Lung Cancer 118:83-89
Perrin, Thomas; Midya, Abhishek; Yamashita, Rikiya et al. (2018) Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging. Abdom Radiol (NY) 43:3271-3278
Apte, Aditya P; Iyer, Aditi; Crispin-Ortuzar, Mireia et al. (2018) Technical Note: Extension of CERR for computational radiomics: A comprehensive MATLAB platform for reproducible radiomics research. Med Phys :
Santini, Fernando C; Rizvi, Hira; Plodkowski, Andrew J et al. (2018) Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res 6:1093-1099
Ma, Jennifer; Setton, Jeremy; Lee, Nancy Y et al. (2018) The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun 9:3292

Showing the most recent 10 out of 8799 publications